Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUCAR-G39P in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
NCT06295549Phase 1Terminated
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Apr 2024
- Primary completion
- Jun 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LUCAR-G39P cells in B-cell non-Hodgkin lymphoma, sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: Incidence, severity and type of Treatment-Emergent Adverse Events, Pharmacokinetics in peripheral blood and 2 more. Started Apr 2024; status: terminated.
02
Drugs
LUCAR-G39P cells
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT06295549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06295549.